Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
07/16/2018
Trade Name:
Intelence
Generic Name or Proper Name (*):
etravirine
Indications Studied:
Treatment of HIV-1 infection in patients 2 years to less than 6 years of age weighing at least 10 kg
Label Changes Summary:
*Expanded the patient population to include pediatric patients 2 years to less than 6 years weighing at least 10 kg; previously approved in pediatric patients 6 years and older. *Use in pediatric patients 2 years to less than 6 years of age is supported by evidence from adequate and well-controlled studies in adults with additional data from a study in 20 pediatric patients 2 years to less than 6 years. *Treatment is not recommended in pediatric patients less than 2 years. *The pharmacokinetics and dose of etravirine in pediatric patients less than 2 years have not been established. *Safety was similar to that observed in adults. *Information on adverse drug reactions, pediatric trial. *Postmarketing study.
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B,P
Sponsor:
Janssen
NNPS:
FALSE
Therapeutic Category:
Antiviral
-
-